MIA contributes to major research breakthrough which pioneers a new way of treating cancer
1 June 2015
Melanoma Institute Australia (MIA) has had a strong presence at the American Society of Clinical Oncology (ASCO) congress in Chicago; where the best ever results seen in metastatic melanoma treatment clinical trial have been presented. Two large international trials, to which MIA contributed, have shown that combinations of new melanoma drugs result in major improvements in disease control and patient survival compared to current therapy.
One study (CheckMate 067), presented in the plenary session, was the first phase 3 trial to combine modern immunotherapy drugs in any cancer. The trial demonstrated improvements in both tumour response and patient survival with the combination of ipilimumab (Yervoy®) with the PD-1 antibody nivolumab (Opdivo®) compared to either therapy given alone. This is not only a major advance for melanoma treatment, but provides the impetus to attempt this approach in other cancer types and with other drug combinations.
Updated results were presented from a second study of targeted therapy (COMBI-D), where a BRAF inhibitor (dabrafenib) was combined with a MEK inhibitor (trametinib) and compared to BRAF inhibitor treatment alone. Again, patients responded better and lived longer with better quality of life with the combination treatment, cementing this as the new standard targeted therapy treatment for metastatic melanoma for patients with BRAF-positive tumours.
Associate Professor Georgina Long of MIA and the University of Sydney, co-author on these studies, says, “Melanoma Institute Australia is leading the way and making major steps forward in cancer history. Two large clinical trials presented at ASCO show that two drugs are better than one for improving patient outcome, both for targeted therapies and immunotherapies, and are the new way of treating cancer.”
In April an international study to which MIA contributed the highest number of patients found that the PD-1 antibody pembrolizumab (KEYTRUDA®) prolonged survival and had less high-grade toxicity compared with ipilimumab (YERVOY®) in patients with advanced melanoma, where melanoma has spread to distant parts of the body. The results from this latest announcement at ASCO prove that the combination of immunotherapy drugs is a better alternative for the majority of melanoma patients.
“MIA has already broken ground with the PD-1 study that showed that the PD-1 antibody pembrolizumab is better than current treatments for patients with advance melanoma, reducing the size of tumours in 70% of patients and recording a one year survival rate of 74% - where it had previously been 58%. The latest findings of combination immunotherapies are the next level of how we treat not just melanoma, but cancer around the world,” Associate Professor Alex Guminski, Clinical Researcher and Consultant Medical Oncologist, Melanoma Institute Australia.
“The latest results are more great news for patients with melanoma, and have implications for all cancer patients. By focusing on the science behind cancer, we can design further treatments that improve response and survival, and hopefully even cure some people,” says Assoc Professor Long.
Help us continue our work. Donate now.
Australasian Melanoma Conference AMC2021
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
Predicting disease spread in thin melanoma
A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.
Exploring our own clinical questions through MIA's new trials initiative
MIA has recently established a new division of our Clinical Trials Program which co-ordinates and manages investigator-led multi-centre trials.
Young researchers awarded Fellowships to pursue innovative treatments for melanoma
Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.
Young researchers receive boost to develop innovative treatment for melanoma
Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.
Launch of Melanoma March 2021
Aussies urged to leave their footprint on melanoma as efforts step up to save lives from the disease.
WA Melanoma Community Forum
An evening for WA melanoma patients, carers and the wider melanoma community, where speakers will provide updates on melanoma research, treatment and support.
Olivia Vivian announced as MIA ambassador
Olivia is using her Ninja star power to shine a spotlight on melanoma prevention - in memory of her dad.
Melanoma breakthrough - neoadjuvant treatment saving lives.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.
Melanoma breakthrough - neoadjuvant therapy saving lives.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.
A message to all Australians from melanoma patient Stuart Taylor
Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate.
Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.
A Ninja Warrior legend and Olympic gymnast, Olivia knows first hand the devastating impact of melanoma.
It's 'Game On Mole' this summer!
All Australians are urged to join the fight against melanoma this summer.
Prof Richard Scolyer named Outstanding Cancer Researcher of the Year
The ground-breaking work of MIA's Co-Medical Director Prof Richard Scolyer has been recognised with NSW’s highest accolade for cancer research.
Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award
A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.
MIA researchers feature on prestigious Highly Cited Researchers 2020 List
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.
Game On Mole is back this summer!
The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.
RCPA recognition for Professor Richard Scolyer.
Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.